Byetta, Bydureon, Bydureon BCise
Evidence Grade A — Regulatory approved. 2741 published studies. 278 registered clinical trials.
Loading...
Exenatide (sold as Byetta and Bydureon) was the first GLP-1 medication to reach the market and is based on a naturally occurring protein discovered in Gila monster saliva. Approved for type 2 diabetes, it mimics the gut hormone GLP-1 to help control blood sugar and promote modest weight loss. Available as a twice-daily or once-weekly injection.
2,741 published studies: 1863 human, 339 animal, 200 in-vitro, 821 reviews
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg.
The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Exenatide works by activating the same GLP-1 receptor as your body's natural gut hormone, but it resists the enzyme that normally breaks GLP-1 down within minutes. This means its effects last much longer. It stimulates insulin release when blood sugar is high, reduces the hormone that raises blood sugar, slows digestion, and curbs appetite. Uniquely, exenatide is derived from a protein found in Gila monster venom that naturally has these GLP-1-like properties, which scientists were able to develop into a diabetes treatment.
Exenatide holds an important place in medical history as the drug that validated the GLP-1 receptor as a treatment target, launching what became one of the most successful drug classes in modern medicine. Clinical trials showed blood sugar reductions (HbA1c) of 1.6-1.9% and modest weight loss of 2-4 kg. However, the large cardiovascular outcomes trial (EXSCEL, involving over 14,700 patients) narrowly missed showing a heart benefit — a result that positioned exenatide behind liraglutide, semaglutide, and dulaglutide in treatment guidelines. The once-weekly formulation (Bydureon) was discontinued in the US in January 2024 due to declining market share as newer, more effective GLP-1 treatments took over. Interestingly, exenatide is being studied for potential neuroprotective effects in Parkinson's disease, with early trial results showing encouraging signals.
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Exenatide For Reducing the Reinforcing Effects of Cocaine
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
Diabetes Islet Preservation Immune Treatment
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
FDA ORIG 1
FDA SUPPL 4
FDA SUPPL 5
FDA SUPPL 6
FDA SUPPL 2
FDA SUPPL 7
FDA SUPPL 12
FDA SUPPL 10
FDA SUPPL 18
FDA SUPPL 22
FDA SUPPL 25
FDA SUPPL 17
FDA SUPPL 9
FDA SUPPL 11
FDA SUPPL 26
FDA SUPPL 28
Health Canada Market Authorisation
EMA Marketing Authorisation
FDA SUPPL 31
FDA SUPPL 30
FDA SUPPL 29
FDA SUPPL 34
FDA SUPPL 35
FDA SUPPL 38
FDA SUPPL 37
FDA SUPPL 39
FDA SUPPL 36
FDA SUPPL 40
FDA SUPPL 41
FDA SUPPL 43
FDA SUPPL 44
FDA SUPPL 45
FDA SUPPL 46
FDA SUPPL 47
FDA SUPPL 48
FDA SUPPL 49
FDA ORIG 1
FDA SUPPL 50
FDA SUPPL 51
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
Octreotide is marketed as Sandostatin (approved 1988), Sandostatin LAR monthly depot (approved 1998), and Mycapssa oral capsules (approved June 2020 — the first oral somatostatin analogue). It is used for acromegaly, carcinoid syndrome, VIPomas, and gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The PROMID trial demonstrated that octreotide LAR significantly delayed tumour progression in patients with neuroendocrine tumours of the midgut, establishing somatostatin analogues as a standard treatment for these cancers. The approval of Mycapssa as an oral formulation was a significant advance for patients who had been receiving monthly injections for years. Octreotide has been on the market for over 35 years and has one of the longest safety track records of any peptide medication.
